Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD study of atuzaginstat in healthy volunteers
NCT03331900Phase 1Completed
- Sponsor
- IRulya Therapeutics
- Start
- Dec 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing Placebo with COR388 (2 arms). Primary endpoints: Area under the plasma concentration curve at 72 hours, Maximum observed plasma concentration at 72 hours and 1 more. Started Dec 2017; status: completed.
02
Drugs
atuzaginstat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03331900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03331900.